Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RIZATRIPTAN BENZOATE vs PATADAY TWICE DAILY RELIEF
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin 5-HT1B/1D receptor agonist; binds with high affinity to 5-HT1B and 5-HT1D receptors, leading to vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission, thereby reducing migraine-associated neurogenic inflammation.
Pataday (olopatadine) is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits the release of histamine and other inflammatory mediators from mast cells, reducing allergic conjunctivitis symptoms.
Acute treatment of migraine with or without aura in adults.,Acute treatment of migraine with or without aura in pediatric patients 6 to 17 years of age.
Treatment of ocular itching associated with allergic conjunctivitis
5-10 mg orally at onset of migraine; may repeat after 2 hours if headache recurs; maximum 30 mg in 24 hours.
1 drop in each affected eye twice daily (approximately every 6-8 hours)
2-3 hours in adults; clinically, no significant accumulation with multiple dosing.
The terminal elimination half-life of olopatadine is approximately 8-12 hours in healthy adults, supporting twice-daily dosing for sustained therapeutic effect.
Primarily metabolized by monoamine oxidase A (MAO-A) via oxidative deamination; minor metabolism by aldehyde oxidase. The major metabolite is the inactive N-desmethyl rizatriptan.
Olopatadine undergoes minimal hepatic metabolism. Systemic absorption is low after ocular administration; the small absorbed fraction is metabolized by CYP3A4 and other CYP450 enzymes.
Primarily hepatic metabolism via monoamine oxidase-A, with ~14% excreted unchanged in urine; total recovery of radioactivity in urine is ~82% (30% unchanged drug, 52% metabolites) and ~9% in feces over 24 hours.
Olopatadine is predominantly eliminated via renal excretion, with approximately 60-70% of the dose recovered as unchanged drug in urine. The remaining 30-40% is eliminated as metabolites (including N-demethylated and N-oxide derivatives) primarily via urine, with minor fecal excretion (<5%).
14%
Olopatadine is approximately 55% bound to plasma proteins, primarily albumin.
140 L (approximately 2 L/kg in adults), indicating extensive tissue distribution.
The volume of distribution (Vd) of olopatadine is approximately 1.3 L/kg, indicating extensive distribution into tissues beyond plasma volume.
Oral: ~45% (due to first-pass metabolism); intranasal: ~42% (compared to subcutaneous sumatriptan); orally disintegrating tablet: ~45%.
Bioavailability via ocular route: Systemic absorption is minimal; however, following topical ocular administration, the systemic bioavailability is approximately 0.5-1% due to low absorption through the conjunctiva and nasolacrimal duct.
No dosage adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
No dosage adjustment required for any degree of renal impairment. No specific GFR-based recommendations provided by manufacturer.
Not recommended in patients with severe hepatic impairment (Child-Pugh class C) due to absence of studies. For mild to moderate impairment (Child-Pugh A or B), no specific dose adjustment; use caution.
No dosage adjustment required for any degree of hepatic impairment. No specific Child-Pugh based recommendations provided by manufacturer.
Children 6-17 years: 5-10 mg orally at onset; may repeat after 2 hours; maximum 30 mg per 24 hours. Weight <40 kg: start 5 mg. Weight ≥40 kg: may use 10 mg.
Children 2 years and older: 1 drop in each affected eye twice daily. Safety and efficacy in children under 2 years have not been established.
Elderly patients may have increased risk of adverse effects. Start at 5 mg; use caution with comorbidities and concomitant medications. No specific dose adjustment required; monitor cardiovascular status.
No specific dosage adjustment required; geriatric patients should use the same dose as younger adults. Elderly may be more susceptible to local adverse effects; monitor for excessive tearing, conjunctival irritation, or dry eye symptoms.
None
None
Risk of myocardial ischemia and/or infarction, coronary artery vasospasm, cerebrovascular events, and increased blood pressure. Serotonin syndrome (especially when co-administered with other serotonergic drugs). Use only after clear diagnosis of migraine; not for use in hemiplegic or basilar migraine. Caution in patients with risk factors for coronary artery disease. Avoid use within 24 hours of other 5-HT1 agonists or ergotamine derivatives. Monitor for signs/symptoms of serotonin syndrome.
Not for injection,Patients should not wear contact lenses if eyes are red,May cause transient burning or stinging,Contains benzalkonium chloride which may be absorbed by soft contact lenses
History of ischemic heart disease (angina, myocardial infarction, silent ischemia), coronary artery vasospasm (Prinzmetal's angina), or other significant cardiovascular disease. Uncontrolled hypertension. Hemiplegic or basilar migraine. Use within 24 hours of another 5-HT1 agonist or ergotamine-containing medication. Concurrent use or within 2 weeks of monoamine oxidase inhibitor (MAOI) therapy. Known hypersensitivity to rizatriptan or any component. Severe hepatic impairment (Child-Pugh class C).
Hypersensitivity to olopatadine or any component of the formulation
No significant food interactions. However, high-fat meals may delay absorption. Avoid alcohol as it may worsen headaches or increase side effects.
No known food interactions. Avoid rubbing eyes which may worsen symptoms.
Rizatriptan is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, rizatriptan was not teratogenic in rats or rabbits but was associated with embryo-fetal toxicity at maternotoxic doses. Use only if potential benefit justifies potential risk to the fetus. First trimester: no specific data, but theoretical risk of vasoconstriction. Second and third trimesters: may cause uterine contractions or reduced uterine blood flow.
No evidence of human teratogenicity. Animal studies show no malformations at clinically relevant doses. Risk cannot be ruled out; use only if clearly needed.
Rizatriptan is excreted in human milk at very low levels; the milk-to-plasma ratio is approximately 0.07. The estimated infant dose is about 3% of the maternal weight-adjusted dose. Caution is advised; consider the developmental and health benefits of breastfeeding along with the mother's clinical need for rizatriptan and potential adverse effects on the breastfed infant.
Unknown if excreted in human milk. M/P ratio not determined. Caution advised; consider developmental risks.
No specific dose adjustments are recommended for pregnancy; however, pharmacokinetic changes in pregnancy (increased plasma volume, altered metabolism) may reduce exposure. Use lowest effective dose for shortest duration. If migraine severity warrants, standard dosing (5-10 mg oral, may repeat after 2 hours, max 30 mg/24h) may be used.
No dose adjustment required. Pharmacokinetic changes in pregnancy not clinically significant.
Rizatriptan is a selective 5-HT1B/1D receptor agonist used for acute migraine. Onset of action is rapid (30 min). Maximum daily dose is 30 mg (oral tablets) or 30 mg (ODT). Do not use within 24 hours of other triptans or ergotamines. Contraindicated in patients with ischemic heart disease, uncontrolled hypertension, or basilar/hemiplegic migraine. Avoid in patients with moderate/severe hepatic impairment. ODT dissolves quickly and can be taken without water, useful for patients with nausea.
Pataday Twice Daily Relief contains olopatadine 0.1%, an ophthalmic mast cell stabilizer and antihistamine. Use for prevention of ocular itching in allergic conjunctivitis. Advise patients to wait 10 minutes after administration before inserting contact lenses. Monitor for transient stinging or blurred vision. Not for treatment of contact lens-related irritation.
Take at the first sign of migraine headache; it will not prevent attacks.,Do not exceed 30 mg in any 24-hour period (separate doses by at least 2 hours).,If first dose does not work, do not take a second dose for the same attack without consulting your doctor.,Seek emergency care if you experience chest pain, shortness of breath, or sudden severe headache.,Inform your doctor if you have heart disease, high blood pressure, or are taking MAOIs (within 2 weeks) or other migraine medications.
Use exactly as prescribed: one drop in each affected eye twice daily (every 6-8 hours).,Wash hands before instilling drops. Do not touch the dropper tip to any surface.,Remove contact lenses before use; wait at least 10 minutes before reinserting.,Do not use if solution changes color or becomes cloudy.,Common side effects include mild stinging or burning upon instillation, which usually resolves.,Avoid driving or operating machinery immediately after use if vision is blurred.
"Co-administration of rizatriptan, a selective 5-HT1B/1D receptor agonist, with sertraline, a selective serotonin reuptake inhibitor (SSRI), increases the risk of serotonin syndrome due to additive serotonergic effects. This potentially life-threatening condition is characterized by neuromuscular excitation, autonomic instability, and altered mental status. Patients should be monitored for symptoms such as hyperthermia, rigidity, myoclonus, and tachycardia, especially during initiation or dose escalation."
"Paroxetine, a selective serotonin reuptake inhibitor (SSRI), inhibits the metabolism of rizatriptan, a triptan used for migraine, via CYP1A2 and possibly other pathways, leading to increased rizatriptan plasma concentrations. This elevates the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular abnormalities, autonomic instability, and altered mental status. Clinically, patients may experience symptoms such as hyperthermia, rigidity, myoclonus, and tachycardia, requiring prompt recognition and management."
"The combination of rizatriptan, a serotonin 5-HT1B/1D receptor agonist, and ziprasidone, an atypical antipsychotic with serotonergic activity (5-HT2A antagonist and weak serotonin reuptake inhibition), may increase the risk of serotonin syndrome. Serotonin syndrome is a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. This additive serotonergic effect occurs through overlapping mechanisms, including enhanced 5-HT1A and 5-HT2A receptor activation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RIZATRIPTAN BENZOATE vs PATADAY TWICE DAILY RELIEF, answered by our medical review team.
RIZATRIPTAN BENZOATE is a 5-HT1 Agonist that works by Selective serotonin 5-HT1B/1D receptor agonist; binds with high affinity to 5-HT1B and 5-HT1D receptors, leading to vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission, thereby reducing migraine-associated neurogenic inflammation.. PATADAY TWICE DAILY RELIEF is a Ophthalmic Antiallergic Agent that works by Pataday (olopatadine) is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits the release of histamine and other inflammatory mediators from mast cells, reducing allergic conjunctivitis symptoms.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RIZATRIPTAN BENZOATE and PATADAY TWICE DAILY RELIEF depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RIZATRIPTAN BENZOATE is: 5-10 mg orally at onset of migraine; may repeat after 2 hours if headache recurs; maximum 30 mg in 24 hours.. The standard adult dose of PATADAY TWICE DAILY RELIEF is: 1 drop in each affected eye twice daily (approximately every 6-8 hours). Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RIZATRIPTAN BENZOATE and PATADAY TWICE DAILY RELIEF in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RIZATRIPTAN BENZOATE is classified as Category D/X. Rizatriptan is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, rizatriptan was not teratogenic in rats o. PATADAY TWICE DAILY RELIEF is classified as Category C. No evidence of human teratogenicity. Animal studies show no malformations at clinically relevant doses. Risk cannot be ruled out; use only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.